Preliminary investigations of mAbs to IL‐9, IL‐13, IL‐17, and IL‐4/IL‐13 are ongoing but optimized formulations of mAb therapy for allergy or asthma are still several years away from clinical use 150. The gene discussed is IL17A; the disease is allergic disease.